冠昊生物
(300238)
| 流通市值：40.17亿 | | | 总市值：40.17亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 121,854,759.37 | 106,780,152.15 | 106,645,462.87 | 109,740,423.08 |
| 应收票据及应收账款 | 57,946,787.32 | 59,545,736.88 | 63,709,363.04 | 60,853,799.21 |
| 应收账款 | 57,946,787.32 | 59,545,736.88 | 63,709,363.04 | 60,853,799.21 |
| 预付款项 | 9,668,348.23 | 2,075,119.15 | 7,257,944.54 | 4,842,970.48 |
| 其他应收款合计 | 2,300,314.45 | 2,205,177.66 | 6,250,244.7 | 6,310,162.3 |
| 存货 | 73,838,054.27 | 78,459,032.6 | 75,276,629.78 | 70,836,315.79 |
| 其他流动资产 | 16,823,995.27 | 16,724,518.68 | 14,474,663.91 | 12,648,646.28 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 282,432,258.91 | 265,789,737.12 | 273,614,308.84 | 265,232,317.14 |
| 非流动资产: | | | | |
| 长期股权投资 | 48,490.18 | 4,489,812.53 | 19,316,439.23 | 16,825,242.45 |
| 其他权益工具投资 | 18,000,000 | 18,000,000 | 15,154,545.45 | 15,154,545.45 |
| 投资性房地产 | 8,457,946.21 | 8,569,230.25 | 8,680,514.29 | 8,791,798.33 |
| 固定资产 | 316,579,858.34 | 319,541,816.39 | 154,925,372.7 | 157,389,008.14 |
| 在建工程 | 2,542,364.88 | 2,542,364.88 | 124,105,646.48 | 100,487,550.91 |
| 使用权资产 | 9,138,937.54 | 10,383,342.13 | 11,938,658.04 | 13,509,884.94 |
| 无形资产 | 77,827,893 | 72,701,685.89 | 76,257,925.21 | 73,881,757.8 |
| 开发支出 | 27,522,291.54 | 26,619,457.5 | 25,568,848.9 | 23,970,646.52 |
| 商誉 | - | - | 1,753,899.07 | - |
| 长期待摊费用 | 3,057,356.36 | 3,260,108.72 | 3,510,134.61 | 3,760,160.5 |
| 递延所得税资产 | 18,342,913.9 | 18,420,720.17 | 15,055,246.69 | 15,138,799.36 |
| 其他非流动资产 | 292,500 | 4,081,555.83 | 438,500.02 | 605,384.49 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 481,810,551.95 | 488,610,094.29 | 456,705,730.69 | 429,514,778.89 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 764,242,810.86 | 754,399,831.41 | 730,320,039.53 | 694,747,096.03 |
| 流动负债: | | | | |
| 短期借款 | 20,013,819.32 | 20,014,583.21 | 21,014,583.21 | 22,516,249.88 |
| 应付票据及应付账款 | 13,265,856.82 | 35,649,866.21 | 8,554,075.76 | 8,633,079.21 |
| 应付账款 | 13,265,856.82 | 35,649,866.21 | 8,554,075.76 | 8,633,079.21 |
| 预收款项 | 978,836.12 | 720,874.08 | 978,836.12 | - |
| 合同负债 | 27,372,908.72 | 28,762,770.74 | 32,441,686.76 | 27,791,312.57 |
| 应付职工薪酬 | 9,454,046.06 | 18,356,099.97 | 15,763,873.9 | 12,828,327.53 |
| 应交税费 | 12,164,972.99 | 7,982,583.69 | 11,167,086.15 | 12,261,371.56 |
| 其他应付款合计 | 55,167,189.53 | 58,625,557.85 | 65,788,641.2 | 56,593,942.75 |
| 一年内到期的非流动负债 | 5,858,032.52 | 5,720,129.93 | 6,599,689.85 | 6,098,545.08 |
| 其他流动负债 | 1,679,719.48 | 2,158,496.09 | 1,979,279.4 | 1,735,628.36 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 145,955,381.56 | 177,990,961.77 | 164,287,752.35 | 148,458,456.94 |
| 非流动负债: | | | | |
| 长期借款 | 99,000,000 | 76,000,000 | 63,070,097.23 | 46,052,388.9 |
| 租赁负债 | 5,169,909.38 | 6,615,111.89 | 7,288,832.27 | 9,426,313.49 |
| 递延收益 | 19,124,426.97 | 19,428,904.5 | 19,733,382.03 | 20,037,859.56 |
| 递延所得税负债 | 6,679,251.81 | 6,772,950.03 | 4,866,165.84 | 4,875,207.09 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 129,973,588.16 | 108,816,966.42 | 94,958,477.37 | 80,391,769.04 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 275,928,969.72 | 286,807,928.19 | 259,246,229.72 | 228,850,225.98 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 265,155,701 | 265,155,701 | 265,155,701 | 265,155,701 |
| 资本公积 | 594,541,559.87 | 594,541,559.87 | 600,545,861.28 | 600,545,861.28 |
| 其他综合收益 | -46,405,497.26 | -46,388,548.35 | -46,575,005.98 | -46,504,259.75 |
| 盈余公积 | 50,643,420.67 | 50,643,420.67 | 47,110,231.52 | 47,110,231.52 |
| 未分配利润 | -306,727,931.28 | -321,594,027.95 | -319,827,806.21 | -327,515,700.41 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 557,207,253 | 542,358,105.24 | 546,408,981.61 | 538,791,833.64 |
| 少数股东权益 | -68,893,411.86 | -74,766,202.02 | -75,335,171.8 | -72,894,963.59 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 488,313,841.14 | 467,591,903.22 | 471,073,809.81 | 465,896,870.05 |
| 负债和股东权益合计 | 764,242,810.86 | 754,399,831.41 | 730,320,039.53 | 694,747,096.03 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |